Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biovail Buys Old Cardizem Name For New Diltiazem Product

Executive Summary

Biovail's purchase of Aventis' Cardizem line will allow the company to market its once-daily diltiazem under an established brand name.
Advertisement

Related Content

GSK Wellbutrin XL Launch Not Affected By Lost Shipment, Biovail Says
GSK Wellbutrin XL Launch Not Affected By Lost Shipment, Biovail Says
Biovail Vasotec/Cardizem Fixed-Dose Combination Data Expected By July
Biovail Vasotec/Cardizem Fixed-Dose Combination Data Expected By July
Watson/Aventis diltiazem agreement
Watson/Aventis diltiazem agreement
Biovail Cardizem XL NDA Highlights Nighttime Dose For Cardiac AE Prevention
Biovail Cardizem XL NDA Highlights Nighttime Dose For Cardiac AE Prevention
Biovail opens new front in Andrx diltiazem dispute
Forest/Biovail Tiazac "Late-Listed" Patent Could Delay Andrx Generic
Advertisement
UsernamePublicRestriction

Register

PS037128

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel